{"disease":{"id":"advanced-hr-her2-negative-breast-carcinoma","name":"advanced hr her2 negative breast carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05295043","title":"Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT05252416","title":"(VELA) Study of BLU-222 in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":50,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT05167643","title":"H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}